United States Cancer gene therapy market 2025: Industry Developments, Future Growth, Share & Industry Insights | Bluebird Bio Inc., Krystal Biotech Inc., Regulus Therapeutics, Biogenera

Cancer gene therapy market size reached US$ 3.36 Billion with rise of US$3.97Billion in 2024 is expected to reach US$ 19.97Billion by 2033, growing at a CAGR of 19.8%during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Cancer Gene Therapy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/cancer-gene-therapy-market?sg

Key Players: Novartis AG, Pfizer, Adapt immune Therapeutics, Bluebird Bio, Inc., Krystal Biotech, Inc., Regulus Therapeutics and Biogenera.

Key scientific / regulatory developments:

✅ 2025-06-26: FDA eliminated REMS (Risk Evaluation and Mitigation Strategies) for currently approved autologous CD19- and BCMA-directed CAR-T therapies, easing post-marketing restrictions and expected to streamline patient access.

✅ 2025-06-19: Major proof-of-concept academic work published demonstrating in-vivo CAR-T generation (directly programming T cells inside the patient) a high-impact preclinical/early-clinical advance that accelerated investment and new trials in 2025.

Mergers & acquisitions:

✅ 2025-01-08: Roche completed its acquisition/tender offer for Poseida Therapeutics (allogeneic CAR-T and non-viral gene platforms) - a ~$1.5B transaction that folded Poseida's CGT assets into Roche.

✅ 2025-03-17: AstraZeneca agreed to acquire EsoBiotec (in-vivo CAR-T / injection-based cell therapy tech) in a deal reported up to ~$1B - strengthening AstraZeneca's cell therapy footprint.

✅ 2025-08-21: Gilead (Kite Pharma) announced an agreement to acquire Interius BioTherapeutics (~$350M) to add in-vivo CAR-T / in-body delivery capabilities to Kite's cell therapy portfolio.

Product launches / clinical & regulatory milestones relevant to cancer gene therapy

✅ 2025-04-22: Nadofaragene firadenovec (non-replicating intravesical gene therapy for BCG-unresponsive NMIBC) showed promising clinical data in Japanese patients a notable country-specific clinical/regulatory step for a cancer gene therapy modality. (Japan development/filing activity continued through 2025.)

✅ 2025 (various dates): Multiple in-vivo CAR-T Phase 1 trials moved forward or reported early data in 2025, increasing attention on in-body delivery (less manufacturing complexity vs ex-vivo CAR-T).

Growth Forecast Projected:

The Global Cancer Gene Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cancer Gene Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-gene-therapy-market?sg

Key Segments:

By Technique (In vivo Gene Therapy, Ex vivo Gene Therapy)

By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer, Others)

By Application (Brain Cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, Liver Cancer, Others)

By End-User (Hospitals, Cancer Centers, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cancer Gene Therapy producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cancer Gene Therapy revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cancer-gene-therapy-market?sg

FAQ's

Q1: What is the current size of the Cancer Gene Therapy Market?

A: The Cancer Gene Therapy Market stood at US$3.97Billion in 2024 and is set to experience remarkable growth, reaching US$ 19.97Billion by 2033

Q2: How fast is the Cancer Gene Therapy Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 19.8% from 2025-2033

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/cancer-gene-therapy-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.